Drug intelligence / Profile preview

CMAB819

Development stage: Unknown
Lead developer: Mabpharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CMAB819 is a PD-1 inhibitor monoclonal antibody developed as a biosimilar to nivolumab. It was initially developed by Sinomab Bioscience Ltd. and later by Taizhou Mabtech Pharmaceutical Co. Ltd. The drug was designed to target the PD-1 (Programmed cell death protein 1) pathway, which plays a key role in immune regulation. CMAB819 was being investigated for various oncology indications, including head and neck squamous cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer. However, clinical development appears to have been discontinued.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CMAB819.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMAB819.

Explore the full profile